Correction: Less Radiographic Progression with Adalimumab plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis.

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009-36:1429-41. (1) In the Results section, page 1431, second column; for MTX monotherapy at Week 104, ACR 20/50/70 response rates should be changed from 86%/66%/49% to 86%/66%/43%. (2) In the first column of page 1432, under the heading “Mean ΔTSS and frequency of radiographic progression by level of ACR response,” the first sentence of the section should read: “The mean ΔTSS values were significantly greater for MTX monotherapy than adalimumab plus MTX for each level of ACR response at Week 26 (except ACR70; Figure 2A) and Week 104 (Figure 2B).” (3) In Table 2, page 1435, first column, DAS28 > 2.6 should be changed to DAS28 < 2.6. We regret the errors.